Anixa Biosciences, Inc.

( )
ANIX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 6.42%282.350.0%$4047.51m
BNTXBioNTech SE 8.17%302.690.0%$1321.33m
NVAXNovavax, Inc. 28.90%182.8578.2%$874.24m
AMGNAmgen, Inc. 1.21%211.321.4%$643.80m
GILDGilead Sciences, Inc. 0.22%69.651.0%$510.30m
LGVNLongeveron Inc. -3.31%19.580.0%$453.36m
VRTXVertex Pharmaceuticals, Inc. 0.08%205.221.9%$451.66m
REGNRegeneron Pharmaceuticals, Inc. 1.61%635.092.7%$406.05m
ILMNIllumina, Inc. 5.06%369.433.3%$341.03m
SNSSSunesis Pharmaceuticals, Inc. 2.38%4.310.7%$301.28m
BIIBBiogen, Inc. 1.21%226.831.8%$284.75m
SGENSeagen Inc. 0.30%146.445.8%$152.49m
INCYIncyte Corp. 2.65%66.732.4%$150.12m
EXASEXACT Sciences Corp. 3.12%83.3618.0%$145.51m
BMRNBioMarin Pharmaceutical, Inc. 2.23%86.124.2%$137.03m

Company Profile

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.